1. Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, Anderson BO et al: Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA oncology 2018, 4(11):1553-1568.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394-424.
3. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A et al: Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015, 385(9972):977-1010.
4. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F: Breast cancer. Nature reviews Disease primers 2019, 5(1):66.
5. Britt KL, Cuzick J, Phillips KA: Key steps for effective breast cancer prevention. Nature reviews Cancer 2020, 20(8):417-436.
6. Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, Darcy PK, Loi S: Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC medicine 2015, 13:202.
7. Zhao BS, Roundtree IA, He C: Post-transcriptional gene regulation by mRNA modifications. Nature reviews Molecular cell biology 2017, 18(1):31-42.
8. Huang H, Weng H, Chen J: m(6)A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer cell 2020, 37(3):270-288.
9. Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Lu Z, Deng X et al: A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nature chemical biology 2014, 10(2):93-95.
10. Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS et al: Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell research 2014, 24(2):177-189.
11. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lindahl T, Pan T, Yang YG et al: N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nature chemical biology 2011, 7(12):885-887.
12. Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, Vagbo CB, Shi Y, Wang WL, Song SH et al: ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Molecular cell 2013, 49(1):18-29.
13. Li F, Zhao D, Wu J, Shi Y: Structure of the YTH domain of human YTHDF2 in complex with an m(6)A mononucleotide reveals an aromatic cage for m(6)A recognition. Cell research 2014, 24(12):1490-1492.
14. Zhu T, Roundtree IA, Wang P, Wang X, Wang L, Sun C, Tian Y, Li J, He C, Xu Y: Crystal structure of the YTH domain of YTHDF2 reveals mechanism for recognition of N6-methyladenosine. Cell research 2014, 24(12):1493-1496.
15. Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, Wang Y, Li X, Xiong XF, Wei B et al: RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Molecular cancer 2019, 18(1):46.
16. Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z, Liu Y, Zhang X, Zhang W, Ye L: HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer letters 2018, 415:11-19.
17. Sun T, Wu Z, Wang X, Wang Y, Hu X, Qin W, Lu S, Xu D, Wu Y, Chen Q et al: LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression. Oncogene 2020, 39(31):5358-5372.
18. Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, Huang X, Wang J, Dougherty U, Bissonnette MB et al: Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature 2019, 566(7743):270-274.
19. Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R, Yuan J, Rana TM: m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. The EMBO journal 2020:e104514.
20. Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, Deng X, Li H, Huang Y, Gao L et al: Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer cell 2020, 38(1):79-96 e11.
21. Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, Aplin AE, Lu Z, Hwang S, He C et al: m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nature communications 2019, 10(1):2782.
22. Tang Z, Li C, Kang B, Gao G, Zhang Z: GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic acids research 2017, 45(W1):W98-W102.
23. Yi YC, Chen XY, Zhang J, Zhu JS: Novel insights into the interplay between m(6)A modification and noncoding RNAs in cancer. Molecular cancer 2020, 19(1):121.
24. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S: UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia 2017, 19(8):649-658.
25. Nagy A, Munkacsy G, Gyorffy B: Pancancer survival analysis of cancer hallmark genes. Scientific reports 2021, 11(1):6047.
26. Wilkerson MD, Hayes DN: ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010, 26(12):1572-1573.
27. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nature communications 2013, 4:2612.
28. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z: Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell reports 2017, 18(1):248-262.
29. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(43):15545-15550.
30. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009, 27(8):1160-1167.
31. Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL: m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Molecular cancer 2020, 19(1):53.
32. Chen DS, Mellman I: Elements of cancer immunity and the cancer-immune set point. Nature 2017, 541(7637):321-330.
33. Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue MZ, Ruan M, Wang H, Zhao J, Li Q et al: Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2019, 25(16):5002-5014.
34. Huang H, Weng H, Chen J: The Biogenesis and Precise Control of RNA m(6)A Methylation. Trends in genetics : TIG 2020, 36(1):44-52.
35. Desrosiers R, Friderici K, Rottman F: Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proceedings of the National Academy of Sciences of the United States of America 1974, 71(10):3971-3975.
36. Lee Y, Choe J, Park OH, Kim YK: Molecular Mechanisms Driving mRNA Degradation by m(6)A Modification. Trends in genetics : TIG 2020, 36(3):177-188.
37. Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I, He X, Semenza GL: Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m(6)A-demethylation of NANOG mRNA. Proceedings of the National Academy of Sciences of the United States of America 2016, 113(14):E2047-2056.
38. Zhou X, Han J, Zhen X, Liu Y, Cui Z, Yue Z, Ding L, Xu S: Analysis of Genetic Alteration Signatures and Prognostic Values of m6A Regulatory Genes in Head and Neck Squamous Cell Carcinoma. Frontiers in oncology 2020, 10:718.
39. Anita R, Paramasivam A, Priyadharsini JV, Chitra S: The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients. American journal of cancer research 2020, 10(8):2546-2554.
40. Chang G, Shi L, Ye Y, Shi H, Zeng L, Tiwary S, Huse JT, Huo L, Ma L, Ma Y et al: YTHDF3 Induces the Translation of m(6)A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. Cancer cell 2020, 38(6):857-871 e857.
41. Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J et al: Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell research 2021, 31(2):178-186.
42. Krug K, Jaehnig EJ, Satpathy S, Blumenberg L, Karpova A, Anurag M, Miles G, Mertins P, Geffen Y, Tang LC et al: Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell 2020, 183(5):1436-1456 e1431.
43. Gong Y, Ji P, Yang YS, Xie S, Yu TJ, Xiao Y, Jin ML, Ma D, Guo LW, Pei YC et al: Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell metabolism 2021, 33(1):51-64 e59.
44. Chong W, Shang L, Liu J, Fang Z, Du F, Wu H, Liu Y, Wang Z, Chen Y, Jia S et al: m(6)A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer. Theranostics 2021, 11(5):2201-2217.
45. Zhong J, Liu Z, Cai C, Duan X, Deng T, Zeng G: m(6)A modification patterns and tumor immune landscape in clear cell renal carcinoma. Journal for immunotherapy of cancer 2021, 9(2).
46. Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen EMJ, Varga A et al: Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2018, 24(12):2804-2811.
47. Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R et al: Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 2019, 30(3):397-404.
48. Shulman Z, Stern-Ginossar N: The RNA modification N(6)-methyladenosine as a novel regulator of the immune system. Nature immunology 2020, 21(5):501-512.
49. Nagarsheth N, Wicha MS, Zou W: Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nature reviews Immunology 2017, 17(9):559-572.
50. Fridman WH, Pages F, Sautes-Fridman C, Galon J: The immune contexture in human tumours: impact on clinical outcome. Nature reviews Cancer 2012, 12(4):298-306.